Broad biomolecular substrates

The term Broad biomolecular substrates is a non-specific classification used in pharmacological databases, such as ChEMBL (CHEMBL2363061), to describe the targets of drugs that react with a wide array of cellular components rather than a single defined protein or receptor (Source: ChEMBL Database). This category primarily encompasses cytotoxic agents, such as alkylating agents and platinum-based compounds, which exert their therapeutic effects by forming covalent bonds with nucleophilic sites on DNA, RNA, and proteins (Source: National Cancer Institute). By disrupting the structural integrity of the genome and interfering with essential enzymatic functions, these drugs inhibit rapid cell proliferation, making them effective in treating various cancers and severe autoimmune disorders (Source: StatPearls, Alkylating Agents). However, because these interactions are not localized to a specific molecular pathway, they often result in significant off-target effects and systemic toxicity, including bone marrow suppression and the risk of secondary leukemias (Source: American Cancer Society). Consequently, Broad biomolecular substrates represents a functional grouping for multi-target chemical reactivity rather than a distinct biological entity.

Other names

Non-specific biomolecular targetsMultiple cellular substratesGeneral biomolecular substratesBroad spectrum substrates

Non-specific covalent modification, including alkylation and cross-linking of DNA, RNA, and various cellular proteins, leading to cell cycle arrest and apoptosis.